ESG Data

アンカーリンク用

Regarding the data for FY2022 marked with ★, we have received independent assurance in our SUSTAINABILITY DATA 2023 (PDF version) so as to bolster the reliability of the information. For details, please see the “Independent Practitioner's Assurance.”Governance Data

ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system

Governance Data

Corporate Governance
Item		Scope	Unit	FY2018	FY2019	FY2020	FY2021	FY2022
Board structure	Directors (Total)	Non-consolidated	Persons	8	8	8	8	8
	Independent outside directors	Non-consolidated	Persons	3	3	3	3	3
	Female directors	Non-consolidated	Persons	0	0	1	1	1
Board of Auditors structure	Auditors (Total)	Non-consolidated	Persons	4	4	4	4	4
	Independent outside auditors	Non-consolidated	Persons	2	2	2	2	2
	Female auditors	Non-consolidated	Persons	1	1	1	1	1
Director Remuneration	Total	Non-consolidated	Million yen	360	368	384	428	595*¹
Director Remuneration	President, Representative Director, and Chief Executive Officer	Non-consolidated	Million yen	114	116	126	125	227*¹
Auditor Remuneration	Total	Non-consolidated	Million yen	77	78	83	85	90
Number of Board of Directors meetings		Non-consolidated	Times	13	13	13	15	12
Number of Board of Auditors meetings		Non-consolidated	Times	14	14	19	16	15
Board attendance rate（directors）		Non-consolidated	%	100	100	98.6	100	100
Board attendance rate（auditors）		Non-consolidated	%	100	92.3*²	100	100	97.9

In FY2022, the remuneration system for Members of the Board of Directors was revised. The previous stock-based remuneration-type stock option system was abolished, and the restricted stock-based remuneration system was introduced. As a transitional measure, restricted stocks (75,000 shares) were issued to the Members of the Board of Directors in lieu of abandoning all stock options that had been allocated but not yet exercised (equivalent to 75,000 shares). The "Total" and the "President, Representative Director, and Chief Executive Officer" of Director Remuneration above included the difference between the amount equivalent to the abandoned stock options and the amount included in the costs in FY2022 when the restricted stocks were issued (96 million yen (for the "Total") and 51 million yen (for the "President, Representative Director, and Chief Executive Officer").
The attendance rate of Audit & Supervisory Board Members excluding the Audit & Supervisory Board Member who resigned due to illness on March 27, 2020 was 100%.

Compliance
Item		Scope	Unit	FY2018	FY2019	FY2020	FY2021	FY2022
Compliance training attendance rate		Non-consolidated	%	100	100	100	100	100
Number of reports	Bribery cases	Non-consolidated	Incidents	0	0	0	0	0
	Discrimination and harassment related	Non-consolidated	Incidents	-	22	15	29	22
	Personnel and labor management related	Non-consolidated	Incidents	-	2	1	2	6
	Customer privacy data related	Non-consolidated	Incidents	-	-	-	-	0
	Conflicts of interest related	Non-consolidated	Incidents	-	-	-	-	0
	Money laundering or Insider trading related	Non-consolidated	Incidents	-	-	-	-	0
	Others	Non-consolidated	Incidents	-	44	6	29	22
	Total	Non-consolidated	Incidents	44	68	22	60	50
Number of compliance violations（Disciplinary action cases）	Bribery cases	Non-consolidated	Incidents	0	0	1	0	0
	Discrimination and harassment related	Non-consolidated	Incidents	-	3	1	0	4
	Personnel and labor management related	Non-consolidated	Incidents	-	0	0	1	0
	Customer privacy data related	Non-consolidated	Incidents	-	-	-	-	0
	Conflicts of interest related	Non-consolidated	Incidents	-	-	-	-	0
	Money laundering or Insider trading related	Non-consolidated	Incidents	-	-	-	-	0
	Others	Non-consolidated	Incidents	-	6	0	10	9
	Total	Non-consolidated	Incidents	5	9	2	11	13
Costs for legal violations		Non-consolidated	Million yen	-	-	0	0	0
Number of facilitation payments		Non-consolidated	Incidents	0	0	0	0	0

ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system

Social Data

Research & Development
Item	Scope	Unit	FY2018	FY2019	FY2020	FY2021	FY2022
R&D expenses	Non-consolidated	Million yen	70,008	66,497	62,384	75,879	95,344
Ratio of R&D expenses to net sales	Non-consolidated	%	24.3	22.7	20.2	21.0	21.3

Provision of Growth Opportunities
Item		Scope	Unit	FY2018	FY2019	FY2020	FY2021	FY2022
Average hours and amount spent of training and development per employee		Consolidated	Hours	-	-	-	50.8	54.8
		Consolidated	JPY 10,000	-	-	-	-	12.2
		Non-consolidated	Hours	35.5	30.7	34.1	53.8	55.9
		Non-consolidated	JPY 10,000	-	-	-	-	12.6
Classification by training category	General capability development	Consolidated	Hours	-	39,189	69,080	63,161	63,958
			Participants	-	16,194	16,867	23,013	19,521
			JPY 10,000	-	-	-	-	31,534
		Non-consolidated	Hours	-	-	-	60,479	62,269
			Participants	-	-	-	22,568	19,228
			JPY 10,000	-	-	-	-	30,170
	Professional capability development	Consolidated	Hours	-	57,226	43,214	84,870	80,435
			Participants	-	11,012	13,072	23,414	25,780
			JPY 10,000	-	-	-	-	13,245
		Non-consolidated	Hours	-	-	-	82,325	71,028
			Participants	-	-	-	21,720	24,801
			JPY 10,000	-	-	-	-	11,924
	Compliance training	Consolidated	Hours	-	6,885	3,816	36,179	53,845
			Participants	-	13,999	33,503	38,276	75,669
			JPY 10,000	-	-	-	-	769
		Non-consolidated	Hours	-	-	-	34,811	48,171
			Participants	-	-	-	37,412	73,303
			JPY 10,000	-	-	-	-	529

Employees information
Item		Scope	Unit	FY2018	FY2019	FY2020	FY2021	FY2022
Employees (total)		Non-consolidated	Persons	3,284	3,287	3,319	3,354	3,381
Employees (male)		Non-consolidated	Persons	2,682	2,676	2,688	2,696	2,707
Employees (male)		Non-consolidated	%	81.7	81.4	81.0	80.4	80.1
Employees (female)		Non-consolidated	Persons	602	611	631	658	674
Employees (female)		Non-consolidated	%	18.3	18.6	19.0	19.6	19.9
Contract workers ratio		Non-consolidated	%	0.1	0.1	0.1	0.1	0.3
Temporary staff ratio		Non-consolidated	%	8.9	8.0	8.8	9.3	9.8
Average age (total)		Non-consolidated	Years old	41.8	42.3	42.7	43.0	43.5
Average age (male)		Non-consolidated	Years old	42.6	43.2	43.7	44.1	44.6
Average age (female)		Non-consolidated	Years old	38	38.4	38.5	38.7	38.7
Employee age group ratio	<30 years old	Non-consolidated	%	-	13.3	13.1	13.0	11.4
	30-50 years old	Non-consolidated	%	-	62.1	59.7	58.2	61.0
	>50　years old	Non-consolidated	%	-	24.6	27.2	28.8	27.6
Average consecutive years of employment (total)		Non-consolidated	Years	15.5	16	16.3	16.5	16.8
Average consecutive years of employment (male)		Non-consolidated	Years	16.3	16.8	17.2	17.5	17.9
Average consecutive years of employment (female)		Non-consolidated	Years	12	12.4	12.5	12.4	12.5
Average annual salary of employees		Non-consolidated	JPY 10,000	917	928	937	947	963
Collective bargaining rights holding rate		Non-consolidated	%	-	97.3	95.7	96.0	95.5
Labor union participation rate		Non-consolidated	%	65.1	60.8	62.2	58.6	56.1

Diversity, Equity and Inclusion
Item		Scope	Unit	FY2018	FY2019	FY2020	FY2021	FY2022
Employment of persons with disabilities		Non-consolidated	%	2.28	2.22	2.13	2.38	2.31
Female manager rate*¹		Non-consolidated	%	1.8	1.5	2.8	3.7	4.1
Female junior manager rate		Non-consolidated	%	-	-	-	14.0	15.8
Percentage of Employees Taking Childcare Leave (male)		Non-consolidated	%	4.1	18.3	33.1	50.0	65.2
Percentage of Employees Taking Childcare Leave (female)		Non-consolidated	%	136.8	96.3	93.9	100	97.4
Gender pay gap*²	All employees	Non-consolidated	%	-	-	-	-	67.0
	Full-time employees		%	-	-	-	-	66.8
	Fixed-term eeployees		%	-	-	-	-	72.7

Calculated based on the provisions of the "Act on Promotion of Women's Participation and Advancement in the Workplace" (Act No. 64 of September 4, 2015)
The gender pay gap in our company arises from factors such as "the average age of female employees in main career track positions being 35.4 years, which is 7.9 years younger than the average age of males at 43.3 years" and "the percentage of female employees in main career track position positions being 81.3%, which is 17.3% lower compared to males at 98.6%."

Recruitment
Item		Scope	Unit	FY2018	FY2019	FY2020	FY2021	FY2022
Total number of newemployee hires	Total	Non-consolidated	Persons	161	88	105	131	127
	New graduates	Non-consolidated	Persons	87	71	73	82	68
	Mid-careers	Non-consolidated	Persons	74	17	32	49	59
Ratio of new graduates (male)		Non-consolidated	%	51	66	60	60	67
Ratio of new graduates (female)		Non-consolidated	%	49	34	40	40	33
Replacement rate of managers through internal transfers*		Non-consolidated	%	-	95.0	96.4	94.1	94.4

(Number of employees newly appointed to manager position) : A
(Number of employees promoted to higher manager positions within a manager position) : B
(Number of employees who joined the company as managers) : C
Replacement rate of managers through internal transfers=(A+B-C)/(A+B)

Employee Engagement
Item		Unit	FY2018	FY2019	FY2020	FY2021	FY2022
Actively engaged employees	Total	%	66	-	79	-	68
	Male	%	68	-	80	-	69
	Female	%	57	-	74	-	64
% of employees with top level of engagement*	Total	%	-	-	-	-	21

The survey was conducted on a non-consolidated basis until fiscal 2020, and on a non-consolidated basis plus 100%-owned domestic and overseas subsidiaries in fiscal 2022. In addition, the questionnaire was revised in order to expand the scope of the survey to overseas subsidiaries in fiscal 2022.

Proportion of employees at the highest level on a 5-point scale. Data are not shown until FY 2020 because the survey was performed on a 7-point scale. The target for fiscal 2022 was 36%. The target for fiscal 2023 is also 36%.

Turnover and retention rate
Item	Scope	Unit	FY2018	FY2019	FY2020	FY2021	FY2022
Retention rate after 3 years (total)	Non-consolidated	%	97.8	93.9	96.6	91.5	90.4
Retention rate after 3 years (male)	Non-consolidated	%	96.1	95.4	97.7	93.6	88.6
Retention rate after 3 years (female)	Non-consolidated	%	100.0	90.9	95.3	87.5	93.1
Full-time employee turnover rate (voluntary resignation)	Non-consolidated	%	1.5	1.6	1.2	1.7	1.7
Full-time employee turnover rate (Mandatory retirement, etc.)	Non-consolidated	%	0.6	0.2	1.1	1.7	1.4
Full-time employee turnover rate (total)	Non-consolidated	%	2.1	1.8	2.3	3.4	3.1

Enhancing cultivation of employee-friendly workplaces
Item	Scope	Unit	FY2018	FY2019	FY2020	FY2021	FY2022
Overtime hours	Non-consolidated	hours / month	14.9	13.6	15.3	16.3	15.9
Percentage of paid vacation taken	Non-consolidated	%	56	65	57.5	62.5	66.0

Health and safety
Item		Scope	Unit	FY2018	FY2019	FY2020	★FY2022
Industrial accident	Number of lost-time injuries	Non-consolidated (Employees)	Incidents	1	0	3	1
	Number of lost-time injuries	Non-consolidated (Temporary employees)*²	Incidents	-	1	0	0
	Lost-time injury frequency rate*¹	Non-consolidated (Employees)	-	0.15	0	0.47	0.16
	Lost-time injury frequency rate*¹	Non-consolidated (Temporary employees)*²	-	-	2.09	0	0
	Number of fatalities due to occupational accidents	Non-consolidated (Employees)	Persons	0	0	0	0
	Number of fatalities due to occupational accidents	Non-consolidated (Temporary employees)*²	Persons	-	0	0	0

Lost-time injury frequency rate = (number of lost-time injuries / total number of actual working hours) x 1,000,000
The data on the number of lost-time injuries, the lost-time injury frequency rate and number of fatalities due to occupational accidents for temporary employees were subject to disclosure from FY2019.

Supporting disease prevention, early detection and early treatment
Item		Scope	Unit	FY2018	FY2019	FY2020	FY2021	FY2022
Comprehensive medical examination rate		Non-consolidated	%	99.4	99.7	99.5	99.8	99.9
Cancer screening rate	Stomach cancer screening	Non-consolidated	%	97.3	97.7	95.3	96.5	96.1
	Lung cancer screening	Non-consolidated	%	99.7	99.9	99.9	100.0	99.9
	Colorectal cancer screening	Non-consolidated	%	93.6	95.8	94.7	93.2	93.3
	Breast cancer screening	Non-consolidated	%	88.3	86.7	89.3	92.5	89.0
	Cervical cancer	Non-consolidated	%	42.3	47.3	46.6	52.3	38.9
Smoking rate		Non-consolidated	%	-	18.2	17.0	15.5	14.2
Difference between health age and actual age		Non-consolidated	Years old	-	-1.5	-1.4	-1.8	-1.8

Mental health measures and health promotion
Item		Scope	Unit	FY2018	FY2019	FY2020	FY2021	FY2022
Stress checks rate		Non-consolidated	%	99.4	99.8	99.5	98.7	98.3
Number of participants in walking campaign	Employees	Non-consolidated	Persons	1,169	1,450	1,417	1,582	1,762
	Family	Non-consolidated	Persons	771	987	985	1,027	993
	Temporary staff, etc.	Non-consolidated	Persons	90	124	89	117	165
Walking campaign all employee participation rate		Non-consolidated	%	35	44	42	47	52

ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system

Environmental Data

Overall Picture of Environmental Impact (ONO's Involvement in Environmental Protection)

Annual inputs and outputs are grasped on a regular basis to use as reference data for our efforts to reduce environmental impact (FY2022).

Sites where data were collected: [Non-consolidated] Fujiyama Plant, Joto Pharmaceutical Product Development Center, Yamaguchi Plant, Minase Research Institute, Fukui Research Institute, Tsukuba Research Institute, Head Office, sales offices and other offices, etc. (logistics centers have been added from FY2021 only for waste data)
[Group companies] ONO PHARMA USA, INC., Cambridge, ONO PHARMA UK LTD, London, ONO PHARMA KOREA CO., LTD, Seoul, ONO PHARMA TAIWAN CO., LTD. Taipei, and Ono Pharma UD Co., Ltd.

GHG emissionsSince the figures in the table are rounded, the breakdown totals may not
always coincide with the overall totals (same as environmental data below).
Item			Scope	Unit	FY2018	FY2019	FY2020	FY2021	★FY2022
GHG emissions scope breakdown (Market-basis) (a)	Scope 1 (Breakdown by GHG type)	Energy-derived	Non-consolidated	kt-CO₂	9.0	9.7	10.0	9.8	8.0
		Energy-derived	Group Companies		-	-	-	-	0.0
		Non-energy-derived (HFCs, HCFCs)	Non-consolidated		0.5	0.4	0.1	0.03	0.2
		Non-energy-derived (HFCs, HCFCs)	Group Companies		-	-	-	-	0.0
		Total			-	-	-	-	8.2
	Scope 2		Non-consolidated	kt-CO₂	19.1	17.1	15.9	13.7	10.2
			Group Companies		-	-	-	-	0.1
			Total		-	-	-	-	10.4
	Scope 1+2 (Total)		Non-consolidated	kt-CO₂	28.5	27.3	26.1	23.6	18.4
			Group Companies		-	-	-	-	0.1
			Total		-	-	-	-	18.6
Amount of CO₂ offset due to voluntary credit(Carbon-neutral city gas purchased) (b)			Non-consolidated	kt-CO₂	-	-	-	0.6	0.7
GHG emissions after offset (a-b)			Subtotal (Non-consolidated)	kt-CO₂	-	-	-	23.0	17.7
GHG emissions after offset (a-b)			Total	kt-CO₂	-	-	-	-	17.9

GHG emissions are calculated using the following formula.
[Domestic sites] GHG emissions = Purchased electricity × Adjusted emission factor published by electric power company + Σ (Fuel consumption × Unit calorific value × Carbon emission factor × 44/12) + Σ (Fluorocarbon leakage amount × Global warming potential)
[Overseas sites] Calculated by multiplying the amount of electricity purchased at overseas sites by the electric utility company's emission factor or the country-specific emission factor published by the IEA.
The amount of green electric power certified under the Green Energy Certificate and , the amount of renewable energy certified under the J-Credit Scheme and the Non-Fossil Fuel Certificate quota are deducted.

GHG emissions in the supply chain (Scope3)
Category		Calculation method	Notes	Scope	Unit	FY2018	FY2019	FY2020	FY2021	★FY2022
C1	Purchased goods and services	GHG emissions (scope 1,2) volume of our major suppliers of raw materials and materials (accounting for 80% or more of our raw materials or materials purchase costs) multiplied by the ratio of the sales to ONO out of the total sales of the supplier. Ratios for other business suppliers are assumed to follow the same trend as for major suppliers, and are calculated using the ratio of GHG emissions to the transaction amount at major suppliers.	·This category is closely associated with our business activities since active pharmaceutical ingredients for manufacturing of drugs, intermediate products and research reagents are included. ·Covers production and research sites	Non-consolidated	kt-CO₂	8.1	11.5	12.7	13.8	-
C2	Capital goods	Amount of capital goods treated as fixed assets (reinforcement of facilities/maintenance investment) excluding land, multiplied by factor	Calculated based on capital goods treated as fixed assets. The fixed assets used in this calculation are essential for business activities.		kt-CO₂	60.4	26.9	25.8	26.4	21.3
C3	Fuel- and energy-related activities not included in scope 1 or scope 2	Amount of non-renewable electricity purchased, multiplied by emission factor	-		kt-CO₂	1.5	2.8	2.7	2.4	2.1
C4	Upstream transportation and distribution	Transport data on deliveries from our production sites and distribution centers to destinations, multiplied by emission factor	-		kt-CO₂	0.1	0.1	0.1	0.1	0.1
C5	Waste generated in operations	Weight of each type of industrial waste generated, multiplied by emission factor	-		kt-CO₂	0.3	0.3	0.3	0.3	0.3
C6	Business travel	Business travel costs, multiplied by emission factor	Covers travels by airplane or Shinkansen bullet train		kt-CO₂	2.3	4.0	0.4	0.5	1.3
C7	Employee commuting	Commuting costs, multiplied by emission factor	'Includes the amount for commuting by car from 2021		kt-CO₂	0.4	0.5	0.4	0.7	0.7
C8	Upstream leased assets	Fuel consumption used in leased vehicles, multiplied by emission factor	-		kt-CO₂	3.3	2.9	2.0	2.1	1.9
C9	Downstream transportation and distribution	GHG emissions on our major pharmaceutical wholesalers, multiplied by percentage of our net sales included in all net sales of major pharmaceutical wholesalers	·Transportation and　distribution are important business activities to control distribution of and to ensure stable supply of drugs.		kt-CO₂	5.3	4.9	5.0	5.5	-
C10	Processing of sold products	-	We make only finished products		kt-CO₂	Not relevant	Not relevant	Not relevant	Not relevant	Not relevant
C11	Use of sold products	-	No energy is consumed during the use of ONO products		kt-CO₂	Not relevant	Not relevant	Not relevant	Not relevant	Not relevant
C12	End-of-life treatment of sold products	Weight of each type of our product container or packaging disposed of as waste, multiplied by emission factor	-		kt-CO₂	0.2	0.2	0.2	0.1	0.2
C13	Downstream leased assets	Floor space of asset (building) owned and rented out categorized by use, multiplied by emission factor	-		kt-CO₂	0.3	0.3	0.3	0.3	0.3
C14	Franchises	-	ONO does not operate franchises		kt-CO₂	Not relevant	Not relevant	Not relevant	Not relevant	Not relevant
C15	Investments	-	There is no investment involving large amounts of greenhouse gas emissions.		kt-CO₂	Not relevant	Not relevant	Not relevant	Not relevant	Not relevant
Total					kt-CO₂	82.2	54.4	49.8	52.3	-

The emission factors used for calculation are figures stated in the "Emission Factor Database on Accounting for Greenhouse Gas Emissions throughout the Supply Chain (FY2018, Ver. 2.6;
FY2019, Ver. 3.0; FY2020, Ver. 3.1; FY2021, Ver. 3.2; FY2022, Ver. 3.3)," published by the Ministry of the Environment, Government of Japan.
Categories 1 and 9 and their total for FY2022 are not calculated because our major suppliers and pharmaceutical wholesalers had not published their GHG at the time of calculation.
Only category 2 is consolidation.

Energy consumption
Item	Scope	Unit	FY2018	FY2019	FY2020	FY2021	★FY2022
Energy consumption	Non-consolidated	MWh	93,763.8	101,605.6	103,204.3	99,499.9	86,067.6
	Group Companies		-	-	-	-	344.1
	Total		-	-	-	-	86,411.7

Total electricity consumption and share of renewable energy
Item		Scope	Unit	FY2018	FY2019	FY2020	FY2021	FY2022
Electricity consumption	Private power generation (renewable) (solar power generation)	Non-consolidated	MWh	65.0	63.0	63.3	61.9	64.4
		Group Companies		-	-	-	-	0.0
	Purchased electricity (renewable) (Non-fossil fuel)	Non-consolidated		-	1,278.0	1,954.7	2,040.0	3,480.0
	Purchased electricity (renewable) (Non-fossil fuel)	Group Companies		-	-	-	-	0.0
	Private power generation (non-renewable)	Non-consolidated		8,856.2	8,185.3	8,566.3	8,283.7	7,285.0
	Private power generation (non-renewable)	Group Companies		-	-	-	-	0.0
	Purchased electricity (non-renewable)	Non-consolidated		43,734.4	46,351.7	45,232.2	42,833.5	37,821.6
	Purchased electricity (non-renewable)	Group Companies		-	-	-	-	343.7
	Subtotal (Non-consolidated total electricity consumption)			52,655.5	55,878.0	55,816.5	53,219.2	48,651.0
	Total (total electricity consumption)			-	-	-	-	48,994.7
Amount of credits purchased	Solar power generation	Fujiyama Plant/Tsukuba Research Institute/Fukui Research Institute/Sales offices and other offices	MWh	-	2,427.0	4,946.6	3,937.9	0.0
Amount of credits purchased	Biomass power generation		MWh	2,900.0	2,460.9	386.2	3,000.0	6,907.0
Renewable energy usage*		Total	MWh	2,965.0	6,228.9	7,350.7	9,039.9	★10,451.4
Renewable energy usage rate (renewable energy usage / total electricity consumption)		Subtotal (Non-consolidated)	％	5.6	11.1	13.2	17.0	★21.5
		Total	％	-	-	-	-	★21.3

Renewable energy usage = Private power generation (renewable) + Purchased electricity (renewable) + Amount of credits purchased

Water intake and wastewater volume by site (unit: 1,000 m³)
Site name	River in the area	Wastewater drainage destination	FY2018		FY2019		FY2020		FY2021		★FY2022
Site name	River in the area	Wastewater drainage destination	Water intake volume	Wastewater volume	Water intake volume	Wastewater volume	Water intake volume	Wastewater volume	Water intake volume	Wastewater volume	Water intake volume	Wastewater volume
Fujiyama Plant	Fuji River	River	240.2	178.4	185.0	145.1	157.8	125.0	138.7	110.2	122.9	100.1
Joto Pharmaceutical Product Development Center	Yodo River	Sewer	6.0	6.0	5.1	5.1	4.6	4.6	3.9	3.9	22.8	20.9
Yamaguchi Plant	Fushino River	River	8.2	8.2	18.1	18.1	18.6	17.7	21.6	20.0	3.4	3.4
Minase Research Institute	Yodo River	Sewer	41.2	41.2	39.1	39.1	33.7	33.7	31.5	31.5	32.2	32.2
Fukui Research Institute	Kuzuryu River	Sewer	31.3	5.0	27.3	5.7	13.7	2.6	6.6	1.9	0.8	0.2
Tsukuba Research Institute	Lake Kasumigaura	Sewer	6.0	6.0	7.1	7.1	7.2	7.2	7.0	7.0	4.7	4.7
Head Office and other sites in Japan (including tenant locations)	Rivers/lake in the areas around each business site*	Sewer	15.1	15.1	15.0	15.0	10.0	10.0	10.0	10.0	9.5	9.5
Total			348.0	259.9	296.7	235.2	245.6	200.8	219.4	184.5	196.4	171.2

Major basins: Toyohira River, Okura River, Arakawa River, Sakawa River, Kiso River, Lake Biwa, Yodo River, Ota River, Yoshino River, Naka River

Waste Management, and Recycling Containers and Product Packaging
Item		Scope	Unit	FY2018	FY2019	FY2020	FY2021	FY2022
Industrial waste	Waste generated	Non-consolidated	t	446.4	430.8	502.7	479.1	★492.8
	[Waste breakdown] Special management industrial waste (hazardous waste)*		t	145.6	161.9	171.2	170.3	★142.5
	final landfill disposal		t	0.4	0.2	1.1	0.2	★0.1
	final landfill disposal rate		%	0.1	0.1	0.2	0.04	★0.02
final landfill disposal (Non-industrial waste is included)			t	9.4	6.7	5.9	5.3	4.4
Container and packaging usage	Plastic	Non-consolidated	t	171.7	162.8	161.5	147.0	173.4
	Paper		t	202.7	200.9	198.1	175.6	163.4
	Glass (colorless)		t	0.0	0.0	0.0	0.0	0.0
	Glass (brown)		t	0.3	0.3	0.2	0.2	0.2
Obligatory recycling amount	Plastic		t	35.5	31.2	35.1	36.6	52.2
	Paper		t	1.6	1.5	1.4	1.3	0.8
	Glass (colorless)		t	0.0	0.0	0.0	0.0	0.0
	Glass (brown)		t	0.0	0.0	0.0	0.0	0.0
Commissioning fee paid for recycling			1,000 yen	1,650	1,546	1,814	1,958	3,049

Special management industrial waste (hazardous waste) is defined under the Waste Management and Public Cleansing Law as waste that has properties of explosiveness, toxicity, infectiousness, and/or possibly causing damage to human health or the living environment.

Prevention of Air Pollution and Water Pollution
Item		Scope	Unit	FY2018	FY2019	FY2020	FY2021	FY2022
Emissions into the air	SOx	Non-consolidated	t	0.0	0.0	0.0	0.0	0.0
	NOx		t	8.4	8.1	8.1	8.3	4.9
	Particulate matter		t	0.28	0.33	0.32	0.34	0.26
	PRTR substance		t	0.25	0.15	0.35	0.32	0.28
Emissions into water	Wastewater		1,000m³	244.8	220.2	190.8	174.5	★171.2
	BOD		t	2.2	1.3	1.2	1.3	1.2
	PRTR substance		t	0.0	0.0	0.0	0.0	0.0

Management of Chemicals (PRTR substances)
Item		Scope	Unit	FY2018	FY2019	FY2020	FY2021	FY2022
Amount handled by the notified facilities	Acetonitrile	Non-consolidated	t	7.2	8.5	10.4	9.3	6.9
	Normal-hexane		t	2.8	3.0	2.6	2.3	1.8
	Total		t	10.0	11.5	13.0	11.6	8.7
	Dioxins		mg-TEQ	-	-	-	-	-
Notified release (into the air)	Acetonitrile		t	0.2	0.1	0.3	0.3	0.3
	Normal-hexane		t	0.0	0.0	0.0	0.0	0.0
	Total		t	0.2	0.1	0.3	0.3	0.3
	Dioxins		mg-TEQ	-	-	-	-	-
Notified release (into public waters)	Acetonitrile		t	0.0	0.0	0.0	0.0	0.0
	Normal-hexane		t	0.0	0.0	0.0	0.0	0.0
	Total		t	0.0	0.0	0.0	0.0	0.0
	Dioxins		mg-TEQ	-	-	-	-	-
Notified transfer (contained in waste)	Acetonitrile		t	6.9	8.4	10.1	8.9	6.6
	Normal-hexane		t	2.8	3.0	2.6	2.3	1.8
	Total		t	9.8	11.3	12.7	11.3	8.4
	Dioxins		mg-TEQ	-	-	-	-	-
Notified transfer (Into public sewage)	Acetonitrile		t	0.0	0.0	0.0	0.0	0.0
	Normal-hexane		t	0.0	0.0	0.0	0.0	0.0
	Total		t	0.0	0.0	0.0	0.0	0.0
	Dioxins		mg-TEQ	-	-	-	-	-
Notified release and transfer (total)	Acetonitrile		t	7.2	8.5	10.4	9.3	6.9
	Normal-hexane		t	2.8	3.0	2.6	2.3	1.8
	Total		t	10.0	11.5	13.0	11.6	8.7
	Dioxins		mg-TEQ	-	-	-	-	-

Management of Chemicals (PCB)
Item	Unit	FY2018	FY2019	FY2020	FY2021	FY2022
In use	Number of units	2	2	2	2	2
Stored PCB	Number of units	552	0	0	0	0

In FY2019, 552 units of stored PCB-using equipment were properly disposed of by contractors licensed to dispose of PCBs.

Environmental Management
Item	Scope	Unit	FY2018	FY2019	FY2020	FY2021	FY2022
Status of acquisition of ISO 14001 certification	Non-consolidated	site	100%	100%	100%	100%	100%

Scope of ISO 14001 certification at production sites.

Environmental Violations
Item	Scope	Unit
Number of breaches of legal obligation/regulatory violations	Non-consolidated	Cases
Amount of breach-/violation-related fines		Million yen
Environmental liabilities as of fiscal year-end		Million yen

Breach/violation cases with fines of USD 10,000 or more
The above includes violations related to air and soil pollution, noise, vibration, and water quality.

ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system

Social Contribution Activities Data

Initiatives for medical advancement
Item	Scope	Unit	FY2017	FY2018	FY2019	FY2020	FY2021
Osamu Hayaishi Memorial Award	-	Persons	1	1	1	1	1
Recipients of theresearch grant	-	Persons	12	12	12	12	12
Recipients of theresearch scholarship grant（40 years old and below）	-	Persons	16	16	16	16	16
Recipients of the Osamu Hayaishi Memorial Scholarship for Study Abroad	-	Persons	8	8	8	8	8

ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system